Provisions Thalidomide Restructuring Other Total million million million million At 30 June 2012 178 80 143 401 Exchange differences 1 3 3 5 Provisions charged during the year 19 32 51 Provisions utilised during the year 23 31 49 103 Unwinding of discounts 10 1 11 At 30 June 2013 164 71 130 365 Included in current liabilities 13 49 47 109 Included in non-current liabilities 151 22 83 256 164 71 130 365 Provisions by their nature are subject to uncertainties with respect to the timing and outcomes of future events.
a A provision was established in the year ended 30 June 2005 in respect of the discounted value of the groups commitment to the UK Thalidomide Trust, and will be utilised over the period of the commitment up to 2037.
Additional provisions were made in the years ended 30 June 2012 and 30 June 2010 in respect of anticipated future payments to additional thalidomide claimants and these will be utilised up to 2030. b The group is engaged in a number of restructuring programmes, which involve the rationalisation of certain operations around the world.
Employee charges, incremental costs in respect of service contract and information systems infrastructure charges in connection with the programmes are recognised in the restructuring provision, which is expected to be substantially utilised by 30 June 2015 see note 5 a - d. c The largest item in other provisions is 52 million 2012 46 million in respect of employee deferred compensation plans which will be utilised when employees leave the company.
Deferred tax assets and liabilities The amounts of deferred tax accounted for in the consolidated balance sheet comprise the following net deferred tax assets liabilities : Property, Post Other plant and Intangible employment temporary equipment assets plans Tax losses differences Total million million million million million million At 30 June 2011 156 613 162 113 233 261 Exchange differences 3 16 4 3 2 22 Recognised in income continuing operations 1 542 45 17 106 675 Recognised in income discontinued operations 5 5 Recognised in other comprehensive income and equity 74 34 33 141 Acquisition of businesses 14 278 9 283 At 30 June 2012 166 1,449 187 161 172 1,095 Exchange differences 4 40 6 2 40 Recognised in income continuing operations 3 48 19 17 37 84 Recognised in other comprehensive income and equity 65 70 105 30 Acquisition of businesses 10 10 At 30 June 2013 167 1,537 109 108 248 1,239 Deferred tax on other temporary differences includes items such as the thalidomide provision, restructuring provisions, share-based payments and intra group sales of products.
After offsetting deferred tax assets and liabilities where appropriate within territories, the net deferred tax liability comprises: 2013 2012 million million Deferred tax assets 243 329 Deferred tax liabilities 1,482 1,424 1,239 1,095 Notes to the consolidated financial statements 169
